AN2 Therapeutics Inc (NASDAQ:ANTX) has a beta value of -0.16 and has seen 1.25 million shares traded in the last trading session. The company, currently valued at $43.62M, closed the last trade at $1.34 per share which meant it gained $0.11 on the day or 8.94% during that session. The ANTX stock price is -1558.21% off its 52-week high price of $22.22 and 35.07% above the 52-week low of $0.87. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.83 million shares traded. The 3-month trading volume is 485.21K shares.

The consensus among analysts is that AN2 Therapeutics Inc (ANTX) is Buy stock at the moment, with a recommendation rating of 3.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.26.

AN2 Therapeutics Inc (NASDAQ:ANTX) trade information

Sporting 8.94% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ANTX stock price touched $1.34 or saw a rise of 8.22%. Year-to-date, AN2 Therapeutics Inc shares have moved -93.46%, while the 5-day performance has seen it change 34.00%. Over the past 30 days, the shares of AN2 Therapeutics Inc (NASDAQ:ANTX) have changed 25.23%. Short interest in the company has seen 0.13 million shares shorted with days to cover at 0.82.

Wall Street analysts have a consensus price target for the stock at $5.5, which means that the shares’ value could jump 75.64% from current levels. The projected low price target is $2.0 while the price target rests at a high of $22.0. In that case, then, we find that the current price level is -1541.79% off the targeted high while a plunge would see the stock gain -49.25% from current levels.

AN2 Therapeutics Inc (ANTX) estimates and forecasts

Figures show that AN2 Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -33.66% over the past 6 months, with this year growth rate of 37.96%, compared to 18.00% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -73.03% over the past 5 years.

ANTX Dividends

AN2 Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

AN2 Therapeutics Inc (NASDAQ:ANTX)’s Major holders

Insiders own 21.64% of the company shares, while shares held by institutions stand at 52.31% with a share float percentage of 66.75%. Investors are also buoyed by the number of investors in a company, with AN2 Therapeutics Inc having a total of 42.0 institutions that hold shares in the company. The top two institutional holders are RA CAPITAL MANAGEMENT, L.P. with over 5.55 million shares worth more than $11.94 million. As of 2024-06-30, RA CAPITAL MANAGEMENT, L.P. held 18.6515% of shares outstanding.

The other major institutional holder is OCTAGON CAPITAL ADVISORS LP, with the holding of over 3.22 million shares as of 2024-06-30. The firm’s total holdings are worth over $6.92 million and represent 10.8196% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . As of Jun 30, 2024 , the former fund manager holds about 2.51% shares in the company for having 749.42 shares of worth $1.0 million while later fund manager owns 261.93 shares of worth $0.35 million as of Jun 30, 2024 , which makes it owner of about 0.88% of company’s outstanding stock.